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A mandibular advancement device is a promising new approach in the treatment of snoring and obstructive sleep apnea. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The device is noninvasive and costs about $400 US in northern Sweden. The effect of the device on sleep-disordered breathing has been reported to vary. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Previous studies have indicated that the success rate with a mandibular advancement device is higher in those with moderate sleep apnea than in those with severe sleep apnea. 5, 10 However, to our knowledge, the effects of the mandibular advancement device on subjects with milder forms of the disease have not been studied. Obstructive sleep apnea is associated with an increased prevalence of cardiovascular complications, such as arterial hypertension, coronary artery disease, and nocturnal angina. [12] [13] [14] The indications for the mandibular advancement device and the routines for following up sleep recordings have not been established. The aim of the present study was to evaluate the effects of a mandibular advancement device on apneas and sleep in patients with mild, moderate, and severe obstructive sleep apnea.
Materials and Methods

Subjects
Forty-three men and four women who did not accept treatment with nasal continuous positive airway pressure or were not offered that treatment because of mild obstructive sleep apnea were invited to participate in the present study. Twenty-six patients were consecutive and thereafter only patients with an obstructive apnea-hypopnea index of Ͼ20 according to preceding sleep apnea recordings were included. Three men of the invited 47 patients refused to take part in the study and were thus excluded from further evaluations. Treatment with mandibular advancement devices was not initiated in patients with CheyneStokes respiration, a body mass index Ͼ40 kg/m 2 , arthralgia or myofascial pain from the craniomandibular system, edentulous jaws, or mesial occlusion. The median age of the 44 patients included in the study was 58 years (range, 37 to 72 years) and the median body mass index was 28 kg/m 2 (range, 22 to 37 kg/m 2 ). Approval for the study was obtained from the Medical Ethics Committee at Umeå University.
The Mandibular Advancement Device
The mandibular advancement device was intended to move the mandible forward by 4 to 6 mm in order to prevent upper airway obstruction and snoring (Fig 1) . An initial advancement of Ͻ4 mm was used in patients with limited protrusion of the mandible and in patients with a tendency toward mesial occlusion. Holes in the acrylic between the incisors and molars provided space for the tongue and permitted mouth-breathing and speech with the appliance in position (Fig 1) . The degree of mandibular advancement was measured on plaster casts in the premolar area and perpendicular to the occlusal plane. The mandibular opening was measured at the central incisors. The mandibular positioning was measured on two separate occasions and the mean value of these measurements was used in the evaluations.
Satisfactory Treatment Result
A satisfactory result was defined as a subjectively evaluated satisfactory reduction in snoring in combination with a decrease in the obstructive apnea-hypopnea index to Ͻ10 during treatment, or as a reduction in the obstructive apnea-hypopnea index of at least 50%. 2 
Study Design
The effect of the device on disturbing snoring was estimated by a bedroom partner or a relative during a 2-month habituation period according to a four-grade questionnaire: "satisfactory effect," "slight effect," "no effect," or "worsened effect." Further mandibular advancement was made, if possible, in patients who did not report a "satisfactory effect." The upper and lower parts of the device were separated and fixed in a new position.
The effects on apneas and sleep were evaluated after the habituation period on 2 separate nights: 1 night without the mandibular advancement device and 1 night with it. The patients were told to sleep without the mandibular advancement device for 1 week prior to the polysomnographic sleep study. The median time between the two polysomnographic recordings was one day (range, 1 to 168 days).
In all patients with an obstructive apnea-hypopnea index of above 10 during treatment, an attempt to further increase the mandibular advancement was initiated. The effects of the adjusted devices on apneas and sleep were evaluated in a second polysomnographic sleep recording in five patients. The present results were obtained from the final polysomnographic sleep recording.
Daytime sleepiness was reported as "reduced," "unaffected," or "never existed."
Polysomnographic Sleep Recordings
Polysomnographic recordings (Nightingale; Judex; Aalborg, Denmark) included EEGs, electro-oculograms, submental electromyograms, nasal and oronasal airflow using a three-way thermistor (Nihon Kohden Ze-732A; Tokyo, Japan), abdominal and chest movements (Resp-EZ; EPM Systems; Midlothian, Va), Sleep stages were scored manually on 30-s epochs according to Rechtschaffen and Kales. 15 An apnea was defined as a cessation of airflow for at least 10 s and a hypopnea as a decrease of Ͼ50% in the thermistor tracing compared with baseline in combination with an oxygen desaturation of Ն3%. An obstructive event was scored if respiratory movements continued during apnea. A concomitant fall in both thermistor tracing and respiratory movements was considered to indicate a central apnea. An arousal was recorded if sleep was interrupted by continuous alpha activity and increased electromyogram activity over 3 s. 16 The apnea-hypopnea index was the average number of events per hour of sleep. The oxygen desaturation index was defined as the average number of oxygen desaturations of Ն4% per hour of sleep. The arousal index was the average number of arousals per hour of sleep. Sleep efficiency was defined as the total sleep time divided by the time from sleep onset to final awakening in the morning.
Mild sleep apnea was defined as an obstructive apnea-hypopnea index of Ͻ20, severe sleep apnea as an obstructive apneahypopnea index of Ն40, and moderate sleep apnea was defined as the values inbetween.
Statistical Methods
Wilcoxon's signed rank test for paired observations, Fisher's Exact Test, Spearman correlation, and one-way analysis of variance were calculated (SPSS 6.1 Statistical Package; SPSS, Inc; Chicago). The null hypothesis was rejected at the 5% level (pϽ0.05).
Results
General Findings
Mild sleep apnea (obstructive apnea-hypopnea index Ͻ20) was defined in 21 of the 44 patients, moderate sleep apnea (obstructive apnea-hypopnea index 20-40) was found in 15 patients, and severe sleep apnea (obstructive apnea-hypopnea indexՆ40) was found in 8 patients. The three severity groups did not differ in terms of age, body mass index, total sleep time, and the percentage of sleep spent in the supine position. Medication, body mass index, and total sleep time did not differ between the two study occasions (Tables 1-3 ). The sleep spent in the supine position increased in patients with mild sleep apnea (pϽ0.05), but was unchanged in patients with moderate and severe sleep apnea.
Effect on Apnea and Hypopnea
The apnea-hypopnea index and the oxygen desaturation index were reduced in all three severity groups (Tables 1-3 and Fig 2) . The median obstructive apnea-hypopnea index decreased during treatment from 11 (range, 7 to 19) to 5 (range, 0 to 17) (pϽ0.001) in patients with mild sleep apnea, from 27 (range, 20 to 38) to 7 (range, 1 to 19) (pϽ0.001) in patients with moderate sleep apnea, and from 53 (range, 44 to 66) to 14 (range, 2 to 32) (pϽ0.05) in patients with severe sleep apnea (Tables 1-3 ). The central and mixed apnea-hypopnea index decreased in patients with mild and moderate sleep apnea (pϽ0.05).
The percentage of sleep spent in apnea or hypopnea decreased during treatment in all three severity groups (pϽ0.05) (Tables 1-3 ). The obstructive apneahypopnea index consisted of fewer apneas than hypopneas during treatment than without the device in all three severity groups (pϽ0.05). 
Effect on Snoring
Snoring was satisfactorily reduced in 20 of 21 patients with mild sleep apnea, in 12 of 15 patients with moderate sleep apnea, and in 5 of 8 patients with severe sleep apnea (Fig 2) .
Satisfactory Treatment Result
An obstructive apnea-hypopnea index of less than 10 and a satisfactory reduction in snoring was found in 17 of 21 patients with mild sleep apnea (81%) during treatment, 9 of 15 patients with moderate sleep apnea (60%), and 2 of 8 patients with severe sleep apnea (25%) (Fig 3) . Thus, 28 of the total of 44 patients had a satisfactory treatment result (64%). The frequency of patients with a satisfactory result correlated inversely with disease severity (rϭϪ0.41; pϽ0.01).
A reduction in the obstructive apnea-hypopnea index of at least 50% together with a satisfactory reduction in snoring was found in 10 of the 21 patients with mild sleep apnea (48%), 10 of 15 patients with moderate sleep apnea (67%), and 3 of 8 patients with severe sleep apnea (38%). A satisfactory result was found in 23 patients in the total sample (52%), using this definition.
Unsatisfactory Treatment Result
Snoring was satisfactorily reduced but the obstructive apnea-hypopnea index was not in 9 of 16 patients with an overall unsatisfactory result (Fig 4) . These patients were regarded as suffering from "silent obstructive apneas." In 2 of the 16 patients with an unsatisfactory result, the obstructive apnea and hypopnea reduction was sufficient, although snoring persisted. In the remaining five patients, snoring as well as obstructive apneas and hypopneas were insufficiently reduced.
Sleep Stage Patterns
The arousal index decreased during treatment with the device in all three severity groups (pϽ0.05) (Tables 1-3 ). Stage 1 sleep was reduced in patients with mild and moderate sleep apnea (pϽ0.01) (Tables 1 and 2). Slow-wave sleep increased during treatment in patients with moderate and severe sleep apnea (pϽ0.05) ( Tables 2 and 3 ). Rapid eye movement sleep increased in all three severity groups (pϽ0.05) (Tables 1-3 ).
Daytime Sleepiness
Forty-two of 44 patients reported daytime sleepiness before treatment. Thirty-four of these patients reported a reduction in daytime sleepiness with the device. Seven of eight patients with persistent daytime sleepiness were regarded as treatment failures with an obstructive apnea-hypopnea index of Ͼ10 during treatment.
Positioning of the Mandible
The median mandibular advancement in all 44 patients was 6.0 mm (range, 2.3 to 8.5 mm), which corresponded to 58% of maximum protrusion (range, 33 to 89%). The median mandibular opening was 10.0 mm (range, 7.0 to 14 mm). The positioning of the mandible was similar in all three severity groups and did not differ between patients with a satisfactory treatment result and patients with an unsatisfactory treatment result using the device. Satisfactory results with the device were found at mandibular advancements at between 3.5 to 8.5 mm, which corresponded to 41 to 88% of maximum protrusion.
The success rate was higher in the patients who were able to advance the mandible at least 5 mm than in those who were not (pϽ0.01). Among the moderate and severe cases, a satisfactory treatment effect with the device was found only in patients who were able to advance the mandible at least 5 mm during treatment.
Discussion
In the present study, the mandibular advancement device reduced the obstructive apnea-hypopnea index and the arousal index and improved the sleep stage patterns in patients with mild, moderate, and severe sleep apnea. Satisfactory results were found more frequently in those with mild apnea than in subjects with severe apnea. More than 50% of patients who had unsatisfactory results with the device still reported a satisfactory effect on snoring. These patients were regarded as suffering from "silent obstructive apneas." Different indexes and cutoff points have been used to define treatment success with a mandibular advancement device in the treatment of obstructive sleep apnea. Criteria, such as a decrease in the obstructive apnea-hypopnea index to Ͻ10 or 20 2, 5, 10 or a reduction in the obstructive apnea-hypopnea index by Ͼ50%, 2,5,6 have been used. Bonham et al 4 used both an obstructive apnea index of Ͻ10 and a 50% reduction in the obstructive apnea index to define treatment success. However, a cutoff point for treatment success based on the apnea and hypopnea reduction in percent may underestimate the treatment effect in patients with mild sleep apnea and overestimate the effect of the device in patients with a more severe disease. This is illustrated in the present study where 10 of 21 patients with mild sleep apnea experienced a 50% reduction in the obstructive apnea-hypopnea index with the device. Even so, 17 of the 21 patients were satisfied with the treatment in terms of reduced snoring together with an obstructive apnea-hypopnea index of Ͻ10 during treatment. Among the moderate and severe cases, 13 patients experienced a 50% reduction in the apnea frequency, while 11 patients had an obstructive apnea-hypopnea index of Ͻ10 during treatment. We suggest that a satisfactory treatment result should be defined as a satisfactory reduction in snoring together with an obstructive apnea-hypopnea index of Ͻ10, irrespective of the initial apnea-hypopnea index.
There were few central and mixed apneas among the present patients with obstructive sleep apnea. The central and mixed apnea and hypopnea index was unaffected by the device in patients with severe sleep apnea, but decreased slightly in the subjects with mild and moderate apnea.
O'Sullivan et al 10 report that a mandibular advancement device is more effective in patients with an obstructive apnea-hypopnea index of between 20 and 60 than in patients with an obstructive apneahypopnea index of Ͼ60. This is in accordance with the results of the present study, although we also investigated milder cases. The study by O'Sullivan et al 10 evaluated the effect of the mandibular advancement device during 1 night: half the night with the device and half without it. We used 2 full-night polysomnographic sleep recordings to increase the validity in the small subgroups. 17 The patients were also told to sleep without the mandibular advancement device for 1 week prior to the polysomnographic sleep study to avoid a possible long-lasting treatment effect by the device during the study. 18 In previous studies, it has been suggested that mandibular advancement devices reduce the obstructive apnea-hypopnea index to Ͻ10 in between 25% and 73% of patients with obstructive sleep apnea. 2, 4, 5, 8 These disparate results could be explained by various proportions of patients with mild, moderate, and severe sleep apnea among the patients included in those studies. In a similar way, the different results in two recent studies comparing the effect of the mandibular advancement device with nasal continuous airway pressure may be explained by milder cases included in the study reporting a good effect by the mandibular advancement device 19 and more severe cases in the study describing an inferior effect by the mandibular advancement device. 20 Clark et al 8 suggest that Ͼ75% of maximum protrusion is needed for a satisfactory effect. However, unnecessarily large mandibular advancements should be avoided, since the long-term negative side effects on occlusion and the temporomandibular joints are unknown. In the present study, a satisfactory treatment result was found at mandibular advancements ranging from 41 to 88% of maximum protrusion. The results also suggested that larger mandibular advancements are needed for treatment success in the more severe cases. It is difficult to measure the mandibular advancement as the per-centage of maximum protrusion, since the maximum protrusion decreases as the mandibular opening increases. 21 We therefore suggest that the degree of mandibular advancement should be described as a distance and not a percentage of maximum protrusion.
The reason why the mandibular advancement device has less effect on severe cases than on milder ones is unknown. It is suggested that large obstructions extending from the soft palate to the base of the tongue or even to the epiglottis occur more frequently in patients with severe sleep apnea than in patients with mild sleep apnea. 22 It is possible that the mandibular advancement device eliminates limited obstructions more effectively, while more extended obstructions are influenced to a lesser degree by the mechanism of the device.
Normal sleep is characterized by 2 to 5% of stage 1 sleep, 45 to 55% of stage 2 sleep, 13 to 23% of slow-wave sleep, and 20 to 25% of rapid eye movement sleep in young adults. 17 Arousals and stage 1 sleep increase in patients with obstructive sleep apnea on account of slow-wave sleep and rapid eye movement sleep. 17, 23 The present results indicate that sleep stages and arousal frequency change toward a more normal pattern during treatment with a mandibular advancement device.
One limitation of the present study was the lack of a snoring microphone. Even so, the present study showed that subjective reports on snoring are unreliable in the evaluation of treatment outcome regarding the effect on apneas. Objective testing of treatment effect on apneas and hypopneas is necessary.
In conclusion, treatment with a mandibular advancement device reduces apneas and improves sleep quality in patients with mild, moderate, and severe sleep apnea. A satisfactory treatment result is more likely to occur in patients with milder sleep apnea than in patients with more severe sleep apnea. A follow-up sleep study with the device is necessary in patients with moderate and severe sleep apnea, because of the risk of reduced snoring despite persistent silent obstructive apneas during treatment.
